drugset / Trial / NCT00129038
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
Treatment
Summary
The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone
Timeline
- Start
- 2004-04-01
- Primary completion
- 2007-01-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 25 mg | — |
| Subject | Aspirin | Small molecule | 75 mg | — |
| Subject | Dipyridamole | Other / unclassified | 200 mg | — |